China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

integrating clinical research with clinical practice. The company says that over the coming years its big pharma partners plan to launch studies using the platform across multiple therapeutic ...

ActiGraph, which makes digital tools used in clinical trials, acquired the life sciences business of Biofourmis, once ...

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The "Strategic Intelligence: Big Data in Pharma" report has been added to ResearchAndMarkets.com's offering. A dedicated report examining the pivotal healthcare, technological, macroeconomic, and ...

The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...